Finasteride 2.5

Products description: Unique Pharma - Finasteride 2.5

This overview synthesizes information on Finasteride, the active substance reportedly in Unique Pharma - Finasteride 2.5, from a limited set of key scientific literature and reputable databases. The information presented aims to be current based on sources accessible and reviewed up to August 8, 2025. Medical knowledge and guidelines are constantly evolving; always consult primary sources and healthcare professionals for the absolute most current information.

Finasteride is a synthetic antiandrogen that acts as a 5-alpha-reductase inhibitor. It is used to treat androgenic alopecia (male pattern hair loss) and benign prostatic hyperplasia (BPH) by blocking the conversion of testosterone to dihydrotestosterone (DHT), a potent androgen responsible for these conditions [1, 2].

⚕️Established Medical Uses for Finasteride

Finasteride is a well-established medication with specific therapeutic applications, primarily in men's health [2, 3, 4]:

• Treatment of benign prostatic hyperplasia (BPH) to improve symptoms and reduce the risk of acute urinary retention and the need for surgery.
• Management of androgenic alopecia (male pattern hair loss) by preventing further hair loss and promoting hair regrowth in some individuals.
• In some cases, it is used for the treatment of hirsutism in women, though this is an off-label use.

🔬Mechanism of Action (Scientifically Described for Finasteride)

The primary mechanism of action for finasteride is its selective inhibition of the 5-alpha-reductase enzyme [1, 2, 5]:

• 5-alpha-reductase Inhibition: Finasteride specifically inhibits the Type II 5-alpha-reductase enzyme. This enzyme is responsible for converting testosterone into the more potent androgen, dihydrotestosterone (DHT).
• DHT Reduction: By inhibiting this enzyme, finasteride significantly lowers the levels of DHT in the prostate, scalp, and serum.
• Therapeutic Effects: The reduction in DHT is what leads to the therapeutic effects. In the prostate, lower DHT levels cause a reduction in prostate size, relieving BPH symptoms. In the scalp, reduced DHT levels decrease the miniaturization of hair follicles, leading to a reduction in hair loss and, in some cases, new hair growth.

⚠️Safety and Adverse Effects (Balanced & Fact-Based for Finasteride)

The use of Finasteride (the active substance in Unique Pharma - Finasteride 2.5) is associated with potential adverse effects, which are generally rare but should be monitored [1, 2, 3]:

• Sexual Side Effects: The most commonly reported side effects are sexual in nature and may include a decrease in libido, erectile dysfunction, and a reduction in ejaculate volume.
• Endocrine Effects: Finasteride can lead to breast tenderness or enlargement (gynecomastia).
• Psychological Effects: In rare cases, finasteride use has been linked to depression and anxiety.
• Prostate Cancer Risk: While finasteride reduces the overall risk of prostate cancer, it has been associated with a small increased risk of a rare but aggressive form of prostate cancer.

💉Dosage and Administration (General Medical Context for Finasteride)

Finasteride is administered orally as a tablet. The dosage and duration of treatment are determined by a healthcare professional based on the specific medical indication [2, 3]:

• Individualized Dosing: For BPH, the typical dose is 5 mg per day. For androgenic alopecia, the dose is usually 1 mg per day.
• Professional Monitoring: Regular monitoring by a doctor is crucial to ensure the treatment is effective and to manage any potential side effects.

📚References

1. ResearchGate. A Review on Finasteride: A 5-Alpha Reductase Inhibitor, its Mechanism, Facts and Benefits. Accessed August 8, 2025. https://www.researchgate.net/publication/384048013_A_Review_on_Finasteride_A_5-Alpha_Reductase_Inhibitors_its_Mechanism_Facts_and_Benefits
2. NCBI Bookshelf. Finasteride. Accessed August 8, 2025. https://www.ncbi.nlm.nih.gov/books/NBK513329/
3. Springer. Finasteride in the management of male-pattern hair loss. Accessed August 8, 2025. https://link.springer.com/article/10.1007/s40278-021-94099-4?utm_source=chatgpt.com
4. BMC Urology. A randomized, placebo-controlled trial of finasteride for the treatment of benign prostatic hyperplasia. Accessed August 8, 2025. https://bmcurol.biomedcentral.com/articles/10.1186/1471-2490-2-14
5. MDPI. Finasteride and its effects on the prostate. Accessed August 8, 2025. https://www.mdpi.com/1424-8247/18/7/957

This information is not medical advice. Consult with a doctor to use this product.